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1 Introduction
Genetically modified crops have been in the food supply 
around the world for almost 10 years and are currently 
planted on 222 million acres in 21 different countries [1]. 
In 2005, Roundup Ready soybean was planted on ap-
proximately 89% of the US Acreage (USDA-NASS, 2005. 
http://usda.mannlib.cornell.edu/reports/nassr/field/ [Ac-
cessed: January 11, 2006]) and 60% of the global soy-
bean areas [1], and is the most cultivated biotechnol-
ogy product to date. Roundup Ready soybeans contain 
the cp4 epsps gene from Agrobacterium spp. strain CP4, 
a common soil-borne bacterium that produces the CP4-
enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) 
protein [2]. The CP4 EPSPS protein produced in Roundup 
Ready plants is functionally identical to endogenous 
plant EPSPS enzymes with the exception that CP4 EP-
SPS naturally displays reduced affinity for glyphosate rel-
ative to endogenous plant EPSPS [2]. The EPSPS enzyme 
is part of the shikimate pathway that is involved in the 
production of aromatic amino acids and other aromatic 
compounds in plants [3]. When conventional plants are 
treated with the herbicide glyphosate, the plants cannot 
produce the aromatic amino acids needed to survive.
946
Published in Molecular Nutrition & Food Research 51 (2007), pp. 946–955; doi: 10.1002/mnfr.200600285 
Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Submitted December 20, 2006; revised February 21, 2007; accepted February 22, 2007. 
Serum testing of genetically modified soybeans  
with special emphasis on potential allergenicity  
of the heterologous protein CP4 EPSPS 
Michael Hoff,1 Dae-Yeul Son,2 Michaela Gubesch,1 Kangmo Ahn,3 Sang-Il Lee,3 
Stefan Vieths,1 Richard E. Goodman,4 Barbara K. Ballmer-Weber,5 and Gary A. Bannon6 
1 Department of Allergology, Paul Ehrlich Institute, Langen, Germany 
2 Department of Oriental Medicine Biofood Science, Daegu Haany University, Korea 
3 Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Korea 
4 Food Allergy and Research Program, University of Nebraska, Lincoln, NE, USA 
5 Department of Dermatology, Allergy Unit University Hospital, Zurich, Switzerland 
6 Product Characterization Center, Monsanto Company, St. Louis, MO, USA 
Corresponding author — Dr. Gary A. Bannon, Regulatoy Sciences, Monsanto, 800 N. Lindbergh Blvd., St. Louis , Missouri, 63167, United States; 
email gary.a.bannon@monsanto.com fax 314-634-8619
Abstract
Roundup Ready soy contains the CP4-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein. Serum IgE from two dis-
tinct populations of soy-allergic patients were recruited to determine their IgE-binding specificity. One population consisted of 10 
adult patients from Europe, whose primary diagnosis was soy food allergy with some also having mite allergy. In addition, 6 pri-
marily mite-allergic, 6 food-allergic (celery, carrot, milk, shrimp, walnut, and apple), and 5 non-allergic patients were tested. An-
other population consisted of 13 children from Korea, whose primary diagnosis was atopic dermatitis and secondarily soy and egg 
sensitization. In addition, 11 non-allergic patients were tested. Each patient population was extensively characterized with respect 
to clinical symptoms, specific IgE (CAP) scores, and total IgE. Immunoblots and ELISA assays were developed using serum IgE from 
these patients and soy extracts, CP4 EPSPS, rice extract, ovalbumin, rubisco, purified major peanut allergen Ara h 2, the putative 
soy allergen Gly m Bd 30k and mite allergen Der f 2 proteins as the intended targets. Immunoblot results indicated that soy-aller-
gic patients bound soy extracts but did not specifically bind rubisco or CP4 EPSPS. ELISA results were in general agreement with 
the immunoblot results except that rubisco bound significant quantities of serum IgE from some patients. These results indicate 
that the CP4 EPSPS protein does not bind significant quantities of IgE from two geographically distinct sensitive populations and 
there is no evidence for an increased allergenic potential of this biotech protein. 
Keywords: Atopic, CP4 EPSPS, Food allergy, IgE, Soy allergy 
Abbreviations: CP4 EPSPS = CP4-enolpyruvylshikimate-3-phosphate synthase; GM = genetically modified
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All proteins introduced into commercial genetically 
engineered plants have undergone a rigorous safety as-
sessment to ensure that there is a reasonable certainty 
of no harm prior to their being placed on the market 
for food and feed use. Protein safety is assessed by as-
says that are based on recommendations from a variety 
of regulatory agencies including CODEX, US-FDA, and 
EFSA. Evaluation of protein safety includes assessments 
of a protein’s history of safe use, expression level, mode 
of action, allergenicity, and acute toxicity. Results from 
these assessments are used in a weight of evidence ap-
proach to determine if a protein is likely to pose a risk to 
human or animal health. 
The primary allergy risk to consumers from geneti-
cally modified crops may be placed into one of three 
categories. The first, that represents the highest risk to 
the allergic consumer is the transfer of a known aller-
gen or IgE cross-reacting protein into a food crop. The 
second category is the potential for an increase in the 
endogenous allergenicity of an already allergenic crop 
[4]. The last category involves expression of novel pro-
teins that may become allergens in man [5]. In order to 
mitigate the three categories of potential allergy risk as-
sociated with biotech crops, all genes introduced into 
food crops undergo a series of tests that includes de-
termination of the source of the introduced protein; any 
significant similarity between the amino acid sequence 
of the protein and known allergens; its susceptibility to 
enzymatic degradation; and serum screens using doc-
umented sera from allergic individuals if the protein is 
similar to known allergens or comes from an allergenic 
source [6]. While there is detailed guidance on how to 
perform bioinformatic analyses [7] and pepsin diges-
tive fate studies [8], there is no consensus in the scien-
tific community on the details of how to perform serum 
studies for regulatory agencies. IgE-binding assays such 
as radioallergosorbent tests (RAST; [9, 10]), ELISA [11], 
or immunoblotting assays are available for this type of 
testing. All these assays use IgE fractions of serum from 
appropriately sensitized individuals. Sensitized individu-
als should be allergic to the food from which the trans-
ferred gene was derived as shown by a convincing clin-
ical history [12] or positive responses in double-blind, 
placebo controlled food challenges [9, 13]. 
In this study, our investigation focused on evaluat-
ing whether at-risk individuals, those with food allergy 
to soybeans and plausible exposure to genetically mod-
ified (GM)-soybeans, have developed IgE specific to the 
introduced CP4 EPSPS protein. Two different patient 
populations were used: children with atopic dermatitis 
secondarily diagnosed with soybean and other food al-
lergies (Korean patients) and adult individuals with clin-
ically documented soy allergy (European patients). For 
this purpose, immunoblot and ELISA assays for specific 
IgE were developed and validated, and control proteins 
were included in the screening to correlate the re-
sults obtained with CP4 EPSPS to immune responses to 
known allergenic and non-allergenic proteins. 
2 Materials and methods 
2.1 Patient sera 
2.1.1 Europe 
A total of 22 sera of food-and mite-allergic patients as 
well as 5 normal human sera were collected from Euro-
pean patients (see Table 1). Ten patients (21–57years old 
at the time of sampling) with soy allergy were positive 
in double blind placebo controlled food challenge (DBP-
CFC) or an open soy challenge, or had a convincing his-
tory of anaphylaxis after ingestion of soy protein. Sera 
from other patients (18–60 years old at the time of sam-
pling) with documented allergies to mite (6 patients), 
celery, carrot, apple, milk, shrimp and walnut (1 patient 
each) were utilized as atopic controls in this study. At the 
time of assessment, allergic patients had total IgE levels 
ranging from 21.5 to 2440 kU/L as measured by using 
the Phadia CAP System (Phadia, Uppsala, Sweden). 
2.1.2 Korea 
A total of 13 sera of food-allergic patients and 11 normal 
human sera were collected from Korean patients (see Ta-
ble 2 for details). Ten patients (2–3 years old) exhibiting 
severe atopic dermatitis with accompanying soy allergy 
had a convincing history of allergic reactions to soy pro-
tein and high IgE levels to soy protein in the Phadia CAP 
system. Sera from 3 egg-allergic patients (4 –8 years 
old) also exhibiting severe atopic dermatitis were uti-
lized in this study. At the time of the assessment, allergic 
patients had total IgE levels ranging from 13.8 to 9250 
kU/L as measured by using the Phadia CAP System. 
2.2 Test proteins and extracts 
2.2.1 Soy and rice extracts 
Full-fat flour was extracted from four different commer-
cial varieties of soybean (two Roundup Ready soy va-
rieties and two non-transgenic soy varieties) using 1 X 
PBS (NaCl 0.138 M, KCl 0.0027 M, with 0.05% Tween 20, 
PBST) containing a protease inhibitor cocktail (Roche 
Cat. # 1697498, 1 tablet/50 mL extraction buffer) using 
a ratio of 1 g of flour to 10 mL of buffer. The suspensions 
were mixed with slow agitation in closed sealed tubes 
at 4°C for 2 h. The extracts were clarified by high-speed 
centrifugation (100006or more). The clarified superna-
tants were passed through a 0.20-lm-sterile membrane 
filter. The protein content of the extracts was determined 
by a commercial dye-binding assay (Roth, Karlsruhe, 
Germany) and aliquots were frozen at –20°C until use. 
The rice extracts were prepared in similar manner. 
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2.2.2 CP4 EPSPS proteins 
Plant-and Escherichia coli-produced CP4 EPSPS proteins 
were obtained from Monsanto Company (St. Louis, MO). 
The plant-and E. coli-produced proteins were character-
ized and compared to each other with respect to their 
identity, function, glycosylation status and purity. For 
every criterion, the plant-and E. coli-produced proteins 
met pre-set acceptance criteria for equivalence. The pu-
rity of the plant-produced protein was 85% and the pu-
rity of the E. coli-produced protein was 97% as assessed 
by SDS-PAGE. 
2.2.3 Der f 2 protein 
The purified Der f 2 protein was purchased from Indoor 
Biotechnologies (Charlottesville, VA). This protein was 
purified from mites by affinity chromatography using an 
anti-mite Group 2 mAb. The purity of the Der f 2 protein 
was >95% according to the specifications provided by 
the manufacturer. 
2.2.4 Rubisco and ovalbumin 
The rubisco and ovalbumin proteins were obtained from 
Sigma-Aldrich (St. Louis, MO). Rubisco was prepared 
from spinach leaves and contained both the large and 
small subunits, and was shipped as a partially purified 
powder. 
2.2.5 Ara h 2 and P34 (Gly m Bd 30 k) proteins 
The peanut allergen Ara h 2 was prepared according to 
the methods of Sen et al. [14]. E. coli-produced soy aller-
gen P34 protein was obtained from Monsanto Company. 
2.3 SDS-PAGE and Western blotting 
The extracts and purified proteins were separated by SD-
SPAGE according to Laemmli [15]. Extracts and proteins 
were reduced by heating with 2x SDS-PAGE reducing 
gel loading buffer (Laemmli Buffer, Bio-Rad cat. # 161-
0737; mixed 1:20 with 2-mercaptoethanol, Bio-Rad cat. 
# 161-0710) and loaded into each well of a gradient gel 
Table 1. European patients: chinical and serological characteristics 
Patient  DOB  Allergy  Clinical *  DBPCFC**                        CAPS (kU/L)   CAPS   Total IgE  
   symptoms  (+/ – )      (kU/L)   (kU/L)
     Soy  Mite  Other  Gly m 4 
  Soy    
1  07/10/70   OAS,N,F,BP  –  1 (0.54)  3 (3.98)   3 (3.98)  137 
2  09/10/60   U  +  1 (0.63)  0 (<0.35)   0 (<0.35)  72.2 
3  02/01/82   OAS,D,R  +  1 (0.51)  3 (10.4)   3 (10.4)  21.5 
4  12/20/71   OAS,BI  +  2 (1.59)  3 (9.34)   3 (9.34)  175 
5  08/11/80   OAS,D,N,E,AE  +  3 (9.91)  0 (<0.35)   0 (<0.35)  161 
6  10/27/46   U,AE,BP,K  +  3 (5.05)  6 (100)   6 (100)  2440 
7  11/08/71   OAS,AE,D,E,BP  –  2 (2.10)  0 (<0.35)   0 (<0.35)  284 
8  04/13/77   OAS,U  +  1 (0.65)  2 (0.92)   2 (0.92)  50.7 
9  08/19/71   OAS  +  2 (2.12)  5 (77.7)   5 (77.7)  1435 
10  11/28/81   OAS  +  2 (1.34)  4 (31.23)   4 (31.23)  1695 
  Mite        
11  07/27/85     0 (<0.35)  3 (8.46)    55.1 
12  08/09/73     1 (0.52)  6 (>100)    1245 
13  02/24/62     0 (<0.35)  3 (6.10)    300 
14  07/18/79     0 (<0.35)  6 (>100)    1217 
15  08/09/53     0 (<0.35)  4 (21.3)    222 
16  04/29/85     0 (<0.35)  4 (35.6)    321 
17  05/15/58  Celery  OAS  +  1 (0.52)   3 (4.77)   75.8 
18  04/03/41  Carrot  OAS  +  2 (0.83)   3 (10.3)   954 
19  10/21/69  Milk  BP  –  0 (<0.35)   4 (19.9)   200 
20  01/25/77  Shrimp  D,BP  –  0 (<0.35)   3 (12.2)   131 
21  1968  Walnut  U,GI  –  0 (<0.35)   4 (45.0)   283 
22  1973  Apple  OAS  –  0 (<0.35)   2 (2.93)   362 
  NA        
23  01/04/63     0 (<0.35)     7.31 
24  05/15/76     0 (<0.35)     221 
25  04/18/43     0 (<0.35)     4.36 
26  07/29/70     0 (<0.35)     6.98 
27  09/29/73     0 (<0.35)     4.05 
* AE, angioedema; Bl, blisters of the oral mucosa; BP, blood pressure drop; D, dyspnea; DOB, date of birth; E, Emesis; F, flush; GI, gastrointestinal 
distress; K, conjunctivitis; N, nausea; NA, not allergic; OAS, oral allergy syndrome; R, rhinitis; U, urticaria. 
** Double blind placebo controlled food challenge. 
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(10–20% Tris-Glycine gels, 1.0 mm × 15 wells, Novex pre-
cast gel; Invitrogen cat. # EC61355BOX). Precision Plus 
Protein Standards (Bio-Rad, product # 161-0374) were 
used as molecular weight markers to estimate protein 
size. The separated proteins were transferred onto 0.45-
μm pore-sized PVDF (polyvinylidene fluoride) mem-
brane (Sigma, P-2813) by means of the tank-blotting 
method using a Hoe-fer transfer system with a cooling 
unit (Hoefer® TE22, Amersham Bioscience).
Immunoblots were pre-incubated for 1 h at room 
temperature with blocking reagent (PBST with 2% non-
fat dry milk, NFDM) and then incubated overnight with 
allergic and non-allergic sera diluted 1:10 v/v in blocking 
reagent. Unbound IgE was removed by repeated rinses 
with PBST. For detection of bound IgE the membranes 
were incubated with biotin-labeled goat polyclonal IgG-
anti-human IgE (KPL, Gaithersburg, MD), followed by 
washing and then incubation in NeutrAvidin-HRP (Pierce 
Biotechnology, Rockford, IL). Detection was achieved us-
ing ECL (enhanced chemiluminescence; Amersham, or 
Supersignal from Pierce), with multiple exposure times 
per membrane to provide optimal signal to noise ratio 
on the X-ray films. As a control, one membrane was in-
cubated with the secondary antibody and ECL detection, 
but without human serum to evaluate the specificity of 
the detection system. 
In some cases, inhibition experiments were performed 
by incubating serum samples with soluble inhibitor for 
approximately one hour before adding to pre-blocked 
membranes. Inhibitor proteins were diluted in 2% NFDM 
so that the final concentration of inhibitor, as incubated 
with 1:10 diluted serum, would be 50 μg of inhibitor/mL 
for CP4 EPSPS, rubisco and Ara h 2 and 500 μg of in-
hibitor/mL when using non-GMO or Roundup Ready soy 
extract. Immunoblot incubation and detection were per-
formed as described above. 
2.4 IgE ELISA assay 
Extracts and target proteins (pool of the two Roundup 
Ready soy extracts, rubisco, ovalbumin and CP4 EPSPS 
for the Korean population; for the European sera, oval-
bumin was replaced with Der f 2) were diluted in pH 9.6 
carbonate buffer to coating concentrations of 10 μg/mL 
for extracts and 2 lg/mL for pure proteins and incubated 
in microtiter plates overnight at 4°C in a humidity cham-
ber to coat the wells. The coating solution was removed 
by washing with PBST and nonspecific binding was 
blocked with 2% NFDM in PBST. Serum samples were di-
luted 1:20 v/v in blocking buffer (at room temperature) 
Table 2. Korea patients: chinical and serological characteristics 
Patient  DOB  Allergy  Clinical  DBPCFC                   CAPS (kU/L)   Total IgE 
   symptoms*  (+/ – )     (kU/L) 
     Soy  Egg  Milk  
  Soy      
258  12/03/01   AD,E,I  –  >100  >100  >100  9250 
259  07/17/02   AD,E,I  –  27.1  >100  74.4  2454 
377  06/20/02   AD,E,I  –  0.91  22  2.3  639 
466  09/29/01   AD,E,I  –  14.4  65.9  1.96  424 
537  08/16/02   AD,E,I  –  2.45  15.3  0.75  91.7 
571  05/27/02   AD,E,I  –  65  >100  44.6  2072 
622  10/17/01   AD,E,I  –  >100  51.2  58.9  721 
664  11/23/02   AD,E,I  –  4.99  7.89  0.46  331 
733  04/18/03   AD,E,I  –  7.14  0  0  13.8 
815  06/21/02   AD,E,I  –  >100  63.4  73.8  2495 
  Egg      
86  03/18/97   AD,BA  –  0  4.74  0  1569 
208  04/14/01   AD  –  0  >100  38  699 
414  01/30/00   AD  –  0  >100  0  381 
  NA      
13  03/01/01     0    
14  08/03/00     0    
17  10/25/03     0    
20  07/10/89     0    
21  09/02/03     0    
22  01/30/00     0    
25  08/30/02     0    
26  01/07/04     0    
27  10/10/03     0    
30  09/02/97     0    
31  04/26/91     0    
* AD, atopic dermatitis; BA, bronchial asthma; DOB, date of birth; E, erythema; I, itching; NA, not allergic. 
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160 min prior to addition to aspirated sample wells. 
Plates were incubated for 2 h in a humidity chamber at 
room temperature. Wells were washed three times with 
PBST before the addition of biotinylated goat anti-IgE 
(KPL) which was diluted 1:4000 v/v in PBST. Plates were 
incubated for 160 min at room temperature and then 
washed three times with PBST. NeutrAvidin-HRP (Pierce 
Biotechnology) was diluted 1:8000 v/v in PBST, added to 
sample wells, and incubated for 60 min at room temper-
ature. Plates were washed three times with PBST before 
addition of 100 μL substrate tetramethylbenzidine (TMB) 
from KPL at room temperature. Reactions were stopped 
after 10 min of incubation at room temperature by ad-
dition of 50 μL 6N sulfuric acid and the OD were read at 
450 nm by a microplate reader. 
3 Results 
3.1 Patients and sera characteristics 
The soy-allergic patients tested in this study represent 
two distinct populations that have very different clini-
cal presentations. The European patient population con-
sisted of adults ranging in age from 18 –60 years old at 
the time of sampling that presented with a wide vari-
ety of clinical symptoms after ingestion of soy (Table 1). 
Their total IgE levels ranged from 21.5 –2440 kU/L with 
a population mean of 647 kU/L. The soy CAP values for 
these patients ranged from 1–3 with a population mean 
of 2.4 kU/L. This low soy CAP value for soy-allergic pa-
tients is, at least partly, due to the exclusion of a major 
soy allergen from the CAP assay that these patients rec-
ognize (Gly m 4) [16, 17]. When tested on recombinant 
Gly m 4 CAP, seven out of ten patients were clearly posi-
tive with specific IgE levels of up to 100 kU/L and a mean 
value of 33.4 kU/L for the positive patients (Table 1). 
In contrast, the Korean patient population consisted of 
children ranging in age from 2 –3 years old at the time 
of sampling that presented with clinical symptoms of 
atopic dermatitis that were secondarily diagnosed with 
soy allergy from clinical histories (Table 2). Their total IgE 
levels were much higher than in the European patient 
population ranging from 13.8–9250 kU/L with a popu-
lation mean of 1849 kU/L. The soy CAP values for these 
patients were also much higher than the European pa-
tient population ranging from 0.91–100 kU/L with a 
population mean of 42.2. In addition, many of the Ko-
rean patients showed significant CAP values to both egg 
and milk allergens (Table 2). 
The control for the European population represented 
three different patient groups. One group consisted of 
6 patients with mite allergy, 6 patients with food allergy 
but not soy-allergic, and 5 non-allergic patients. Total IgE 
levels for the mite-allergic patients ranged from 55.1–
1245 kU/L, for the food but not soy-allergic patients from 
75.8–954 kU/L, and the non-allergic patients from 4.05 – 
221 kU/L (Table 1). The control for the Korean population 
represented two different patient groups. One group con-
sisted of 3 patients with atopic dermatitis that were sec-
ondarily diagnosed with egg allergy from clinical histo-
ries and 11 non-allergic patients. Total IgE levels for the 
atopic dermatitis patients secondarily diagnosed with egg 
allergy ranged from 381–1569 kU/L. Total IgE was not de-
termined for the non-allergic patients (Table 2). 
3.2 IgE immunoblot analysis 
A goat anti-CP4 EPSPS antibody was used to probe PVDF 
membranes loaded with E. coli and plant expressed CP4 
EPSPS, the mite allergen Der f 2, the major peanut al-
lergen Ara h2, rubisco, ovalbumin, extracts from two 
Roundup Ready soy varieties and two non-transgenic 
varieties, as well as rice extract (Fig. 1). As expected, the 
CP4 EPSPS protein was detected in the transgenic soy ex-
tract lanes and those lanes loaded with CP4 EPSPS pro-
tein standard. The immuno-detectable level of CP4 EPSPS 
in GM soybean was approximately equivalent to the sig-
nal visible in the 40 ng/lane sample of E. coli produced 
protein and markedly below the 400 ng/lane sample (Fig. 
1), demonstrating the relevance of loading purified sam-
ple at 40 ng as representative for soybean loading for hu-
man IgE assays. An example of the IgE immunoblot re-
sults is indicated in Fig. 2. In all cases, the patient sera 
reacted against positive control extracts and allergens as 
expected. For example, the European soy-allergic patients 
had IgE that recognized protein bands in soy extracts that 
ranged in molecular weight from <10 kDa to >75 kDa. 
There was also significant cross-reactivity with rice extract 
proteins observed (Fig. 2). Similarly, the Korean patients 
with atopic dermatitis secondarily diagnosed with soy al-
lergy also recognized a wide range of soy proteins (<10–
75 kDa) with significant cross-reactivity noted for a vari-
ety of other proteins including ovalbumin, rubisco and 
rice extracts (data not shown). No significant difference in 
binding to extracts of wild-type versus GM soybean was 
observed with any of the allergic patient sera. 
One European soy-allergic patient serum (#8) and 2 
Korean atopic dermatitis patient secondarily diagnosed 
with soy allergy (537, 622) initially reacted with the pure 
transgenic protein, CP4 EPSPS (Fig. 3) on long expo-
sures of the film. The intensity of binding was not strong 
(based on 40 ng loading equivalence to soybean sam-
ples) and was obvious in serum that bound to several 
proteins in soy and rice extracts. In order to determine if 
these sera contained IgE specific to CP4 EPSPS protein, a 
Western blot inhibition experiment was performed (Fig. 
4). In this experiment the CP4 EPSPS protein, rubisco, 
non-transgenic soy extract and transgenic soy extract 
were used separately as inhibitors to determine their ef-
fect on IgE binding. However, in these experiments, and 
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several others, these sera failed to reproducibly bind to 
the CP4 EPSPS protein but did bind to many of the soy 
extract proteins. Furthermore, CP4 EPSPS protein had 
no effect on IgE binding to the soy extract proteins but 
the binding was markedly inhibited with nontransgenic 
and transgenic soy extract proteins, suggesting that 
the binding may be relatively nonspecific. In the case as 
shown in Fig. 4, inhibition with the rubisco protein also 
significantly reduced IgE to the soy extract proteins. 
Since IgE binding to the CP4 EPSPS protein was not re-
producible and binding to soy extract could be inhibited 
by rubisco, it was concluded that there were no specific 
IgE to the CP4 EPSPS protein.
3.3 ELISA analysis 
Preliminary tests were used to determine the opti-
mum concentrations of protein for coating of microtiter 
plates, dilution of serum IgE and biotinylated anti-IgE, 
and optimum times for incubation of reagents to max-
imize specific signals while minimizing nonspecific bind-
ing. Thereafter, all sera were tested according to the final 
Figure 1. CP4 EPSPS protein detection by goat anti-CP4 EPSPS antibodies. Proteins were electrophoresed, immunoblotted, and 
then probed with anti-CP4 EPSPS antibodies to detect the CP4 ESPSPS proteins. Lane 1, molecular weight markers; Lane 2, rubisco 
(400 ng); Lane 3, E. coli-produced CP4 EPSPS (400 ng); Lane 4, E. coli-produced CP4 EPSPS (40 ng); Lane 5, plant-produced CP4 EP-
SPS soybean (40 ng); Lane 6, Roundup Ready soy protein extract 1 (10μg); Lane 7, Non-GM soy protein extract 1(10 μg); Lane 8, 
Non-GM soy protein extract 2 (10 μg); Lane 9, Roundup Ready soy extract 2 (10 μg); Lane 10, molecular weight markers; Lane 11, 
Rice protein extract (10 μg); Lane 12, E. coli-produced soy allergen P34 (Gly m Bd 30 k) (400 ng); Lane 13, plant-produced peanut 
allergen Ara h 2 (400ng); Lane 14, house dust mite allergen Der f 2 (400 ng); Lane 15, egg allergen ovalbumin Gal d 2 (400 ng). 
Figure 2. Serum IgE binding to purified proteins and plant extracts. Proteins were separated by SDS-PAGE, immunoblotted, and 
then probed with serum IgE from a European soy-allergic patient. Lane designations are the same as noted in the Fig. 1 legend. 
Figure 3. Apparent IgE binding to purified CP4 EPSPS protein. Proteins were separated by SDS-PAGE, immunoblotted, and then 
probed with serum IgE from European soy-allergic patient #8. Lane designations are the same as noted in the Fig. 1 legend. 
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protocol as specified in the Section 2. The values in Fig. 
5 reflect the average of three independent wells without 
the background subtracted from the raw OD readings. 
All European patient serum IgE was used in ELISA as-
says with soy extract, rubisco, CP4 EPSPS or Der f 2 pro-
teins as targets. Soy extract-binding values for the Eu-
ropean soy-allergic patient population ranged from 0.44 
to 0.82 with a population mean of 0.54. Mean IgE-bind-
ing values for this same population to rubisco, CP4 EP-
SPS, and Der f 2 were 0.16, 0.05, and 0.36, respectively. 
Mean IgE-binding values for the mite allergic patients 
showed significant binding to Der f 2 (1.21) as expected 
with insignificant levels of IgE binding to rubisco (0.10) 
and CP4 EPSPS (0.052). Mean IgE-binding values of the 
mite allergic patients to soy extracts (0.44) were at the 
lower range of the values obtained for the soy-allergic 
patients. 
Korean patient serum IgE was used in ELISA assays 
with soy extract, rubisco, CP4 EPSPS or ovalbumin pro-
teins as targets. Just as was observed for the soy CAP 
values, ELISA results for the Korean patient population 
were higher than those reported for the European pa-
tients. Soy extract-binding values for the Korean soy-al-
lergic patient population ranged from 0.47 to 2.87 with 
a population mean of 1.21. Mean IgE-binding values for 
this same population to rubisco, CP4 EPSPS, and oval-
bumin were 0.21, 0.06, and 1.31, respectively. Mean IgE-
binding values for the atopic dermatitis patients that 
were secondarily diagnosed with egg allergy showed 
significant binding to ovalbumin (1.26) as expected; with 
insignificant binding to rubisco (0.08), CP4 EPSPS (0.06) 
and soy extract (0.53). 
4 Discussion 
The EPSPS family of enzymes is ubiquitous to plants and 
microorganisms. EPSPS proteins have been isolated from 
both sources, and their properties have been extensively 
studied [18–22]. The EPSPS protein is absent in mam-
mals, fish, birds, reptiles, and insects [19]. The bacterial 
and plant enzymes are mono-functional with molecular 
weights of 44–48 kDa [20]. EPSPS proteins catalyze the 
transfer of the enolpyruvyl group from phosphoenol-
pyruvate (PEP) to the 5-hydroxyl of shikimate-3-phos-
phate (S3P), thereby yielding inorganic phosphate and 
5-enolpyruvylshikimate3-phosphate (EPSP) [21]. Due to 
the specificity of EPSPS for its substrates, the only known 
catalytic product generated is EPSP, which is the penulti-
mate product of the shikimic acid pathway. Shikimic acid 
is a substrate for the biosynthesis of the aromatic amino 
acids (phenylalanine, tryptophan and tyrosine) and other 
aromatic molecules. 
Roundup Ready soy contains the EPSPS gene de-
rived from Agrobacterium spp. strain CP4 (cp4 ep-
sps). The cp4 epsps coding sequence encodes a 47.6-
kDa EPSPS protein consisting of a single polypeptide 
of 455 amino acids [2]. The CP4 EPSPS protein is struc-
turally similar and functionally identical to endogenous 
Figure 4. IgE does not bind CP4 EPSPS protein reproducibly. 
Proteins were separated by SDS-PAGE, immunoblotted, and 
then probed with serum IgE from European soy-allergic patient 
#8 that was unblocked or blocked with CP4 EPSPS, rubisco, 
transgenic soy extract, or non-transgenic soy extract. Lane 1, 
molecular weight markers, Lane 2, CP4 EPSPS E. coli (400 ng), 
Lane 3, rubisco (400 ng), Lane 4, Roundup Ready (RR) soy ex-
tract (10 μg), Lane 5, non-GM soy extract (10 μg), Lane 6, pea-
nut allergen Ara h 2 (400 ng), and Lane 7, egg allergen ovalbu-
min (Gal d 2) (400 ng).
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plant EPSPS enzymes, but has a much-reduced affinity 
for glyphosate, the active ingredient in Roundup herbi-
cides, relative to endogenous plant EPSPS [2]. In con-
ventional plants, glyphosate binds to the endogenous 
plant EPSPS enzyme and blocks the biosynthesis of shi-
kimate-3-phosphate, thereby depriving plants of essen-
tial amino acids [22]. In Roundup Ready plants, which 
are tolerant to the Roundup family of agricultural herbi-
cides, requirements for aromatic amino acids and other 
metabolites are met by the continued action of the CP4 
EPSPS enzyme in the presence of glyphosate [2]. 
Harrison et al. [3] demonstrated the safety of the CP4 
EPSPS protein according to the recommendations of 
the Codex Alimentarius Commission [6]. Briefly, they 
showed that the protein is from a non-allergenic source, 
the protein does not represent a relatively large portion 
of the total protein, the protein does not share struc-
tural similarities to known allergens or toxins based on 
the amino acid sequence, the protein is unstable to di-
gestion in simulated gastric fluid, and the protein is not 
acutely toxic. Furthermore, others [23, 24] showed that 
the endogenous allergenicity of GM soy containing this 
gene is unchanged when compared with non-GM soy. 
These characteristics ensure that the CP4 EPSPS does 
not represent a known allergen and is unlikely to act as 
a cross-reactive allergen. They also demonstrate that it 
is unlikely the transfer of the gene altered the endoge-
nous allergenicity of soy. The data obtained by IgE test-
ing of extracts of GM and non-GM soy in this study con-
firm and underline these findings. Studies designed to 
determine whether the endogenous allergenicity of a 
GM crop has been modified when compared to its non-
GM counterpart have repeatedly shown no change in 
IgE-binding capacity. Perhaps this is not surprising given 
that endogenous allergen expression would have to be 
significantly up-regulated as a result of the gene trans-
fer event. Given the large size of most plant genomes 
and the very limited number of gene encoding allergens 
the trans-gene would have to be inserted proximal to an 
allergen gene in such a way as to up-regulate transcrip-
tion. This seems like it would be an extremely rare event 
and perhaps we should reconsider whether this study 
brings any value to the allergy assessment process.
The studies mentioned above address two of the 
categories of potential allergenic risk to public health 
posed by genetically modified crops; transfer of a 
known allergen or likely cross-reactive protein and the 
potential increase in endogenous allergenicity of an al-
ready allergenic crop [4]. Recently, Batista et al. [25] at-
tempted to test for evidence that CP4 EPSPS may have 
sensitized consumers by performing a post-market se-
rum study to address the third category of allergenic 
Figure 5. ELISA results from Korean and 
European soy-allergic patients. 
(A) Histogram showing IgE binding 
of Korean atopic dermatitis patients 
secondarily diagnosed with soy al-
lergy to different purified proteins and 
extracts. 
(B) Histogram showing IgE binding of 
European soy-allergic patients to dif-
ferent purified proteins and extracts. 
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risk to public health; expression of a novel protein that 
becomes an allergen. In their study serum IgE from a 
wide variety of allergic patients were tested to deter-
mine if they developed IgE to proteins newly introduced 
into food crops after having been exposed to them for 
a long period. The patients had positive histories of 
food allergy or inhalant allergy with the probability of 
these individuals having eaten GM soy containing the 
CP4 EPSPS protein near 100% based on the global dis-
tribution of GM soy containing CP4 EPSPS and ubiqui-
tous use of soy protein in processed foods. Results from 
their study showed that none of the patients tested had 
detectable levels of IgE directed against the CP4 EPSPS 
protein and that there were no discernable differences 
between transgenic and non-transgenic extracts when 
used in skin prick tests [25]. 
In contrast, the present study tested a more focused 
study population that included soy-allergic patients 
from Europe and atopic dermatitis patients that were 
secondarily diagnosed with soy allergy from Korea as 
the test groups. Even though the patient populations 
tested in each of these studies were different there was 
no significant IgE binding to the CP4 EPSPS protein. In 
the IgE ELISA in which the proteins were tested under 
non-denaturing conditions, CP4 EPSPS had the lowest 
IgE-binding capacity of all antigens tested. Binding to 
CP4 EPSPS was even lower than to rubisco, a ubiquitous 
plant protein that has never been described as an aller-
gen, though rubisco clearly bound IgE from some of our 
study participants by ELISA (Fig. 5). In IgE Western blot-
ting experiments, sera from three subjects showed weak 
apparent binding to the biotech protein which could not, 
however, be reproduced in subsequent experiments. In 
attempts to confirm the specificity of the antibody bind-
ing, unspecific effects were observed with soy extracts, 
CP4 EPSPS, and rubisco. In part these effects may be due 
to low affinity binding to plant N-glycans (soybean ex-
tracts), but it is more likely that the high sensitivity of the 
enzyme immunologic detection of the Western blots did 
result in some unspecific binding only visible under the 
denaturing conditions of the Western blot assay, but not 
in the more physiological ELISA test. Therefore, we con-
clude that, 10 years after market introduction and con-
sumption of Roundup Ready soy, our study revealed no 
evidence for allergenicity of the heterologous protein 
CP4 EPSPS. 
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